Scarica l'app Stockscreener
4.14
0.98%
0.04
Pre-mercato:
4.14
Precedente Chiudi:
$4.10
Aprire:
$4.13
Volume 24 ore:
827.94K
Relative Volume:
1.14
Capitalizzazione di mercato:
$928.76M
Reddito:
$596.48M
Utile/perdita netta:
$123.72M
Rapporto P/E:
7.5492
EPS:
0.5484
Flusso di cassa netto:
$106.59M
1 W Prestazione:
+5.08%
1M Prestazione:
+44.25%
6M Prestazione:
+12.81%
1 anno Prestazione:
+13.74%
Intervallo 1D:
$4.02
$4.27
Intervallo di 1 settimana:
$3.99
$4.32
Portata 52W:
$2.215
$5.28
Curevac N V Stock (CVAC) Company Profile
Confronta CVAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
4.14 | 928.76M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | Iniziato | SVB Securities | Outperform |
| 2023-01-19 | Aggiornamento | UBS | Neutral → Buy |
| 2023-01-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-06-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Underperform |
| 2021-04-26 | Iniziato | Guggenheim | Neutral |
| 2020-12-10 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-09-08 | Iniziato | Credit Suisse | Neutral |
| 2020-09-08 | Iniziato | Jefferies | Hold |
Mostra tutto
Curevac N V Borsa (CVAC) Ultime notizie
CureVac (NASDAQ:CVAC) Shares Up 4.7%Should You Buy? - MarketBeat
Jane Street Group LLC Has $235,000 Stock Position in CureVac (NASDAQ:CVAC) - Defense World
Geode Capital Management LLC Lowers Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac NV (FRA:5CV) 50-Day SMA : €2.91 (As of Jan. 11, 2025) - GuruFocus.com
CVAC (CureVac NV) 14-Day RSI : 68.17 (As of Jan. 10, 2025) - GuruFocus.com
CureVac (NASDAQ:CVAC) Trading 5.7% HigherHere's What Happened - MarketBeat
Why CureVac (CVAC) Shares Are Volatile - Benzinga
CureVac: Latest GBM Data Bodes Well For Next Program Check Point (NASDAQ:CVAC) - Seeking Alpha
Why CureVac (CVAC) Stock Is Moving - Benzinga
CureVac (NASDAQ:CVAC) Shares Gap DownHere's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Gap UpHere's Why - MarketBeat
Why CureVac (CVAC) Stock Is Rising - Benzinga
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25% - Simply Wall St
Short Interest in CureVac (NASDAQ:CVAC) Declines By 6.4% - MarketBeat
CureVac (NASDAQ:CVAC) Trading Up 3.6% – Still a Buy? - Defense World
CureVac (NASDAQ:CVAC) Stock Quotes, Forecast and News Summary - Benzinga
CureVac (NASDAQ:CVAC) Stock Price Up 3.6%Here's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Trading Up 4.7%What's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 5.5%What's Next? - MarketBeat
CureVac's SWOT analysis: mRNA pioneer's stock faces oncology pipeline hurdles - Investing.com
2 Small-Cap Stocks Set to Shine in a Bull Market - Benzinga
CUREVAC : Licensing deal boosts bank account - Marketscreener.com
Point72 Asset Management L.P. Sells 1,642,723 Shares of CureVac (NASDAQ:CVAC) - MarketBeat
CUREVAC : Positive one-off overshadows pipeline dryness - Marketscreener.com
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
CureVac NV (XTER:5CV) 50-Day SMA : €2.62 (As of Dec. 05, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 5-Day RSI : 64.31 (As of Dec. 05, 2024) - GuruFocus.com
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal phase in oncology push - Investing.com
CureVac NV (LTS:0A9E) EBITDA per Share : $0.84 (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CureVac NV (WBO:CVAC) Enterprise Value : €94.9 Mil (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Altman Z-Score : 2.46 (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) 9-Day RSI : 62.66 (As of Nov. 30, 2024) - GuruFocus.com
CVACCureVac N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC) - Simply Wall St
CureVac NV (STU:5CV) Total Assets : €854.2 Mil (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) Capex-to-Operating-Cash-Flow : 0.01 (As of Sep. 2024) - GuruFocus.com
Loss-Making CureVac N.V. (NASDAQ:CVAC) Set To Breakeven - Yahoo Finance
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? - MSN
CureVac NV (STU:5CV) Total Inventories : €0.5 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) 50-Day SMA : €2.65 (As of Nov. 21, 2024) - GuruFocus.com
CureVac NV (XTER:5CV) Float Percentage Of Total Shares Outs - GuruFocus.com
CureVac NV (STU:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Retained Earnings : €-1,371.0 Mil (As of Sep. 2024) - GuruFocus.com
CureVac NV (FRA:5CV) Free Cash Flow : €94.5 Mil (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) 3-Year Revenue Growth Rate : -16.20% (As of Sep. 2024) - GuruFocus.com
Curevac N V Azioni (CVAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):